Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 9/20 | 0.45 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242174 | 0.82 | ADORA2A (0.56) | MEN1PRMT5WDR77ADKADORA2A | |
| SCHEMBL17818386 | 0.80 | MEN1 (0.48) | MEN1PRMT5WDR77ADK | |
| SCHEMBL16237556 | 0.80 | SRC (0.48) | MEN1PRMT5WDR77ADKADORA2A | |
| SCHEMBL16254799 | 0.79 | GPR119 (0.59) | MEN1PRMT5WDR77 | |
| SCHEMBL16236292 | 0.78 | MEN1 (0.50) | MEN1PRMT5WDR77ADKADORA2A | |
| SCHEMBL16254729 | 0.78 | METTL3 (0.53) | MEN1PRMT5WDR77ADKADORA2A | |
| SCHEMBL2740574 | 0.76 | ADK (0.48) | MEN1PRMT5WDR77ADK | |
| SCHEMBL14447403 | 0.76 | MEN1 (0.43) | MEN1PRMT5WDR77ADKADORA2A | |
| SCHEMBL17818398 | 0.75 | MAP4K4 (0.49) | MEN1PRMT5WDR77ADK | |
| SCHEMBL13314384 | 0.71 | ADK (0.53) | MEN1PRMT5WDR77ADKMETTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | MEN1 3235/4885PRMT5 188/4885WDR77 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.